Peps
What is Liraglutide?
Liraglutide is an incretin medicine with distinct diabetes and weight-management product contexts. Its benefits should be tied to the exact indication and population.
Biological role or research focus
Incretin signaling, glucose control, and appetite.
Victoza and Saxenda have distinct product contexts; verify the actual prescription label.
Role reference: MedlinePlus · Liraglutide ↗
Names you may encounter
Saxenda · Victoza
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- GLP-1 receptor agonist
- Main research area
- Glucose, appetite, and cardiovascular outcomes
- Evidence featured
- Human randomized trial
- Source check
- October 4, 2026
Source: MedlinePlus · Liraglutide ↗
Molecular structure
Mechanism & research rationale
It supports glucose-dependent insulin release and slows stomach emptying. Appetite and weight changes are related effects, while cardiovascular outcomes require dedicated trials.
Source: MedlinePlus · Liraglutide ↗
Clinical uses & product context
The medication reference covers diabetes control, cardiovascular-risk reduction in selected adults with diabetes, and weight management in eligible patients. Victoza and Saxenda are not interchangeable indications.
Source: MedlinePlus · Liraglutide ↗
What does the evidence show?
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized trial · 2016
LEADER
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
- Population / model
- 9,340 adults with type 2 diabetes and high cardiovascular risk.
- Study design
- Liraglutide versus placebo added to standard care; median follow-up 3.8 years.
- Main finding
- The cardiovascular composite occurred in 13.0% versus 14.9%; hazard ratio 0.87 (95% CI 0.78–0.97). Gastrointestinal events were the commonest reason for stopping treatment.
- Limits & context
- The 1.9-percentage-point difference describes this population and follow-up. This was not a trial of otherwise healthy people or the separate weight-management product indication.
Source: Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. ↗
Human randomized trial · 2015
SCALE Obesity and Prediabetes
Did weight change in adults without type 2 diabetes?
- Population / model
- 3,731 adults with obesity, or overweight with dyslipidemia or hypertension; 61.2% had prediabetes.
- Study design
- 56-week double-blind placebo comparison with lifestyle counseling in both groups.
- Main finding
- Mean weight reduction was 8.4 kg versus 2.8 kg. At least 5% weight loss occurred in 63.2% versus 27.1%. Nausea and diarrhea were common; serious events occurred in 6.2% versus 5.0%.
- How to read it
- This evaluates weight management, whereas LEADER evaluates cardiovascular events in diabetes.
- Limits & context
- The analysis used last-observation-carried-forward imputation. Trial regimen, population, and duration differ from other GLP-1 trials, preventing simple cross-trial rankings. Funded by Novo Nordisk.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Search additional PubMed records ↗New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Safety & precautions
Key precautions
Gastrointestinal symptoms, pancreatitis, gallbladder problems, and dehydration are relevant. Thyroid-tumor warnings and increased hypoglycemia risk with certain diabetes medicines require label-specific review.
Source: MedlinePlus · Liraglutide ↗
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
What are people discussing?
No editorial transcript note has been reviewed for this profile yet. Below are the matching video records available for exploration; title and caption matches are not verified claims.
Watch the source discussions
0 matching video records · 0 with captions indexed.
Across the full library, 30 caption files are indexed from 20,199 inventoried videos. Most transcripts remain unreviewed. Select a thumbnail or timestamp to watch inside PepsRadar. Thumbnail images load from YouTube.
No matching video has been identified in the current snapshot.
Sources & supplier listings
Listings are grouped by the vendor’s stated identity. Blends and modified derivatives are labeled separately. Inclusion is not a quality assessment or an endorsement.
We have not added a supplier for this profile. Missing products and coded listings are not filled with guesses.
Catalog checked 2026-10-04. Seller listings retain their stated intended use. Shops covered: BioLongevity Labs, BioLongevity Supplements, American Peptides, PSPeptides. This is not a market-wide comparison. Affiliate participation does not determine evidence or editorial coverage.
Questions worth asking
- Which indication and formulation does the source describe?
- Does the video make a broader claim than the source supports?
- Victoza and Saxenda have distinct product contexts; verify the actual prescription label.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Was LEADER a general weight-loss study?
No. It studied cardiovascular outcomes in people with diabetes and high cardiovascular risk.
Source: MedlinePlus · Liraglutide ↗
Does the same molecule imply the same product instructions?
No. Brand, indication, formulation, and prescribing instructions still matter.
Source: Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. ↗
References & editorial record
- MedlinePlus · Liraglutide ↗
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. ↗
- SCALE Obesity and Prediabetes · 2015 ↗
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation. Video notes specify which excerpts were reviewed; no full transcripts are published.